New drugs in the treatment of psoriasis.
Psoriasis is one of the most common skin disorders affecting approximately 2% of the population; the disease is recurrent and can be very debilitating. The cause of psoriasis is unknown, although it appears to be an autoimmune disease with a genetic component to its aetiology. Past topical treatments such as emollients, coal tar and dithranol have been messy, cosmetically unacceptable or of low efficacy, while older systemic therapies have suffered from significant side effects. Newer drugs with better therapeutic indexes and new antiproliferative/immunomodulatory therapies based on an increased understanding of the origins of psoriasis have brought us closer to the goal of safely and efficaciously treating the disease. This review will cover the newest topical and systemic drugs currently in use, in clinical trials or preclinical development.
DiSepio
D
D
Department of Retinoid Biology, Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92623, USA. disepio_daniel@allergan.com.
Chandraratna
R A
RA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002762:Cholecalciferol / Q000031:analogs & derivatives*; D003879:Dermatologic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015507:Drugs, Investigational; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D014801:Vitamin A / Q000031:analogs & derivatives*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D015507:Drugs, Investigational; D007166:Immunosuppressive Agents; D014801:Vitamin A; D002762:Cholecalciferol